Adherence to malaria treatment policy and prevalence of Pfkelch13 and background mutations associated with artemisinin resistance emergence in Plasmodium falciparum parasites in Uganda

Predictors of local emergence and spread of artemisinin resistance among Ugandan plasmodium falciparum parasites

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN12267960

Enrollment

385

Registered

2022-04-01

Start date

2021-06-05

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Screening for occurrence of artemisinin resistance among symptomatic malaria patients Infections and Infestations

Interventions

The study is screening for the presence of artemisinin resistance in Plasmodium falciparum parasites among symptomatic malaria patients in low and high malaria transmission settings in Uganda. Microsc

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Symptomatic malaria patients 2. Age 18 years and above 3. Patients with malaria treatment given at a hospital

Exclusion criteria

Exclusion criteria: 1. Severely ill adult malaria patients 2. Anemic patients (males, Hb < 13g/100ml; non-pregnant females, Hb <12g/100ml; pregnant females, Hb <11g/100ml) 3. Patients with low parasite load (<1000 parasites/µl of blood)

Design outcomes

Primary

Measure	Time frame
Artemisinin resistance is measured using K13 gene mutations and background mutations (crt, arps10, fd, mdr-2) at baseline. This being a cross-sectional study, the outcome will be measured once at baseline.	—

Secondary

Measure	Time frame
1. Level of adherence to malaria treatment policy measured using a questionnaire and interview guide at baseline 2. Pharmacopoeial quality of ACTs measured using LC-MS at baseline	—

Countries

Uganda

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026